NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
19 trialsNCT07069270 2025-07-16
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06614621 2024-09-26
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06586697 2024-09-19
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Henan Cancer Hospital
Phase 2 Unknown
NCT06236997 2024-02-01
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT01441349 2022-04-06
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05299255 2022-03-28
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03983759 2020-06-11
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT01441297 2017-08-25
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown
NCT01159327 2015-11-11
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
National Cancer Center, Korea
Phase 2 Terminated
NCT00452634 2013-06-19
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
National Cancer Center, Korea
Phase 2 Completed
NCT00620347 2013-06-19
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT01429766 2011-09-07
A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients
Tata Memorial Hospital
Phase 2 Unknown
NCT00453167 2010-07-12
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed